The Q3 beat is overshadowed by CVI's flat revenue and a weak Q4 outlook for contact lenses. Watch for further channel destocking commentary on the call; the strategic review conclusion and expanded buyback provide a floor, but organic growth concerns at CVI cap upside. Monitor Q4 CVI revenue trajectory for signs of stabilization.
Price Chart
Executive Summary
CooperCompanies reported fiscal Q3 2026 non-GAAP EPS of $1.15, a 2.7% beat vs consensus of $1.12, on revenue of $1.066B (1% YoY growth, in line with $1.10B consensus). However, CooperVision revenue was flat YoY at $717M, and Q4 guidance for CVI organic growth of -2% to 0% signals continued channel inventory headwinds. The company completed its strategic review, expanded its buyback authorization to $3B, and repurchased $339M in stock, but the core contact lens business remains under pressure, making this a mixed read-through for the stock.
Key Financial Metrics
Key Facts
- Non-GAAP EPS of $1.15 beat consensus of $1.12 by 2.7%
- Revenue of $1.066B was slightly below the $1.10B consensus estimate
- CooperVision revenue flat YoY at $717M; Q4 guidance calls for -2% to 0% organic growth
- CooperSurgical revenue grew 2% to $349.2M, with fertility up 5% organically
- Free cash flow rose 66% to $273.0M; $339.1M in stock repurchased during the quarter
- Board expanded buyback authorization from $2B to $3B, with ~$1.5B remaining
- Fiscal 2026 non-GAAP EPS guidance set at $4.51-$4.55; Q4 guidance $1.05-$1.09
- GAAP EPS of $2.24 included a $307.2M discrete tax benefit from UK HMRC examination
Financial Impact
Non-GAAP EPS beat by $0.03 (2.7%) vs consensus; revenue miss of ~$34M (3.1%) vs consensus; Q4 CVI guidance implies -2% to 0% organic decline
Risk Factors
- CooperVision organic revenue declining -2% to 0% in Q4, indicating prolonged channel inventory destocking
- Total revenue guidance of $4.229-$4.252B implies Q4 revenue below consensus expectations
- Non-GAAP EPS guidance of $4.51-$4.55 for FY2026 suggests Q4 EPS of $1.05-$1.09, below the $1.11 Street estimate for the next quarter
- Flat CVI revenue in Q3 and negative Q4 guidance may signal market share loss or demand softness
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3359075 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | Insider Cluster | $54.61 $56.07 | ▲ +2.67% | ▲ +0.11% | $57.28 (+4.89%) |
Sep 14, 2026 17d ago | Press Release | $54.22 $54.12 | ▼ −0.18% | ▼ −0.29% | $57.28 (+5.64%) |
Sep 11, 2026 20d ago | Press Release | $54.22 $54.12 | ▲ +0.18% | ▲ +0.29% | $57.28 (−5.64%) |
Sep 9, 2026 22d ago | Press Release | $54.17 $53.78 | ▼ −0.73% | ▼ −0.23% | $57.28 (+5.74%) |
Jun 4, 2026 17w ago | 8-K | $67.34 $67.88 | ▲ +0.80% | ▲ +0.23% | $57.28 (−14.94%) |
Jun 4, 2026 17w ago | Press Release | $67.34 $67.88 | ▲ +0.80% | ▲ +0.23% | $57.28 (−14.94%) |
Mar 5, 2026 30w ago | 8-K | $76.36 $69.80 | ▼ −8.59% | ▼ −7.06% | $57.28 (−24.99%) |
Mar 5, 2026 30w ago | Press Release | $76.36 $69.80 | ▼ −8.59% | ▼ −7.06% | $57.28 (−24.99%) |
Feb 24, 2026 31w ago | DEFA14A | $83.38 $81.82 | ▼ −1.87% | ▼ −0.77% | $57.28 (−31.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access